Dihydroergocryptine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Summary

Dihydroergocryptine is a dopamine agonist indicated in the treatment of cerebrovascular diseases and atherosclerosis.

Generic Name
Dihydroergocryptine
DrugBank Accession Number
DB13385
Background

Not Available

Type
Small Molecule
Groups
Experimental
Synonyms
Not Available

Pharmacology

Indication

Not Available

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbametapirThe serum concentration of Dihydroergocryptine can be increased when it is combined with Abametapir.
AbataceptThe metabolism of Dihydroergocryptine can be increased when combined with Abatacept.
AbemaciclibThe metabolism of Abemaciclib can be decreased when combined with Dihydroergocryptine.
AbirateroneThe metabolism of Dihydroergocryptine can be decreased when combined with Abiraterone.
AcalabrutinibThe metabolism of Acalabrutinib can be decreased when combined with Dihydroergocryptine.
AcebutololAcebutolol may increase the vasoconstricting activities of Dihydroergocryptine.
AceclofenacThe risk or severity of hypertension can be increased when Aceclofenac is combined with Dihydroergocryptine.
AcemetacinThe risk or severity of hypertension can be increased when Dihydroergocryptine is combined with Acemetacin.
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Dihydroergocryptine.
AcetaminophenThe metabolism of Dihydroergocryptine can be increased when combined with Acetaminophen.
Interactions
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Products

Products2
Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Dihydroergocryptine mesylate5AAV003TAQNot AvailableNot applicable
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
TOTERJİN DAMLA, 50 CCDihydroergocryptine (33 %) + Dihydroergocristine (33 %) + Ergoloid mesylate (33 %)Solution / dropsOralBİLİM İLAÇ SAN. VE TİC. A.Ş.2020-08-142018-08-16Turkey flag
นาลีนDihydroergocryptine mesylate (333 MCG) + Dihydroergocornine mesylate (333 MCG) + Dihydroergocristine mesylate (333 MCG)Tabletบริษัท สหแพทย์เภสัช จำกัด1985-04-02Not applicableThailand flag
เฮลคอนDihydroergocryptine mesylate (333 MCG) + Dihydroergocornine mesylate (333 MCG) + Dihydroergocristine mesylate (333 MCG)Tabletบริษัท โปลิฟาร์ม จำกัด จำกัด1985-06-15Not applicableThailand flag

Categories

ATC Codes
N04BC03 — Dihydroergocryptine mesylate
Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
67V3FSL2GL
CAS number
Not Available

References

General References
  1. FDA Thailand: NALINE (dihydroergocornine, dihydroergocristine, dihydroergocryptine) oral tablets [Link]
RxNav
3417
Wikipedia
Dihydroergocryptine

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Tablet
Capsule
Solution / dropsOral
Solution / dropsOral
Tablet
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
Not Available
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Enzymes

Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. de Mey C, Althaus M, Ezan E, Retzow A: Erythromycin increases plasma concentrations of alpha-dihydroergocryptine in humans. Clin Pharmacol Ther. 2001 Aug;70(2):142-8. doi: 10.1067/mcp.2001.117286. [Article]
  2. Wooltorton E: Risk of stroke, gangrene from ergot drug interactions. CMAJ. 2003 Apr 15;168(8):1015. [Article]

Drug created on June 23, 2017 20:41 / Updated on June 02, 2021 20:04